Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38557758)

  • 1. COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
    Worthington J; Sun Z; Fu R; Lew JB; Chan KKW; Li Q; Eskander A; Hui H; McLoughlin K; Caruana M; Peacock S; Yong JHE; Canfell K; Feletto E; Malagón T
    PLoS One; 2024; 19(4):e0296945. PubMed ID: 38557758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 on hospital screening, diagnosis and treatment activities among prostate and colorectal cancer patients in Canada.
    Lee SH; Ojo AT; Halat M; Bleibdrey N; Zhang S; Chalmers R; Zimskind D
    Int J Health Econ Manag; 2023 Sep; 23(3):345-360. PubMed ID: 37005943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
    Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
    Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
    Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
    Elife; 2023 Apr; 12():. PubMed ID: 37022767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada.
    Yong JH; Mainprize JG; Yaffe MJ; Ruan Y; Poirier AE; Coldman A; Nadeau C; Iragorri N; Hilsden RJ; Brenner DR
    J Med Screen; 2021 Jun; 28(2):100-107. PubMed ID: 33241760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
    Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
    EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
    van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
    Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the potential impact of COVID-19-related disruptions on HIV incidence and mortality among men who have sex with men in the United States: a modelling study.
    Mitchell KM; Dimitrov D; Silhol R; Geidelberg L; Moore M; Liu A; Beyrer C; Mayer KH; Baral S; Boily MC
    medRxiv; 2020 Nov; ():. PubMed ID: 33173893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic.
    Nascimento de Lima P; van den Puttelaar R; Hahn AI; Harlass M; Collier N; Ozik J; Zauber AG; Lansdorp-Vogelaar I; Rutter CM
    Elife; 2023 May; 12():. PubMed ID: 37129468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.
    Loveday C; Sud A; Jones ME; Broggio J; Scott S; Gronthound F; Torr B; Garrett A; Nicol DL; Jhanji S; Boyce SA; Williams M; Barry C; Riboli E; Kipps E; McFerran E; Muller DC; Lyratzopoulos G; Lawler M; Abulafi M; Houlston RS; Turnbull C
    Gut; 2021 Jun; 70(6):1053-1060. PubMed ID: 32855306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian Landscape Assessment of Colorectal Cancer Screening during the COVID-19 Pandemic.
    El Bizri M; Hamidi MW; Mksyartinian P; Stein BD
    Curr Oncol; 2023 Oct; 30(10):8973-8991. PubMed ID: 37887548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Maringe C; Spicer J; Morris M; Purushotham A; Nolte E; Sullivan R; Rachet B; Aggarwal A
    Lancet Oncol; 2020 Aug; 21(8):1023-1034. PubMed ID: 32702310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada.
    Malagón T; Yong JHE; Tope P; Miller WH; Franco EL;
    Int J Cancer; 2022 Apr; 150(8):1244-1254. PubMed ID: 34843106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
    Huntley C; Torr B; Sud A; Rowlands CF; Way R; Snape K; Hanson H; Swanton C; Broggio J; Lucassen A; McCartney M; Houlston RS; Hingorani AD; Jones ME; Turnbull C
    Lancet Oncol; 2023 Jun; 24(6):658-668. PubMed ID: 37178708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding COVID-19 impact on cervical, breast, and colorectal cancer screening among federally qualified healthcare centers participating in "Back on track with screening" quality improvement projects.
    Fisher-Borne M; Isher-Witt J; Comstock S; Perkins RB
    Prev Med; 2021 Oct; 151():106681. PubMed ID: 34217422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring implications of Medicaid participation and wait times for colorectal screening on early detection efforts in Connecticut--a secret-shopper survey.
    Patel VB; Nahar R; Murray B; Salner AL
    Conn Med; 2013 Apr; 77(4):197-203. PubMed ID: 23691732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.